RE: no chat yet15 Dec 2020 07:50
Pablo, Omega aren't equal partners in the RTC, with Abingdon.
Abingdon are on point for 50% of production.
But this, I think, works in our favour. As you point out we have number of other tests that bring us greater profit, which is why Colin has only allocated 200k per week to RTC production.
I've no doubt there are some political schenanigans going on, but feel wholey confident things will all play out in the coming weeks, into the new year.
MHRA approval pending after a "small" evaluation that may now be completed?
FDA approval?
The £75m RTC order (waiting for ABDX to float?)
Mologic - All very quiet on that front, but we know that Mologic met Design Freeze, as Omega are in tech transfer now, and all going well will conclude ready for production in the new year at 300k tests per week.
There is a lot to land news wise. I wonder is ABDX is a reason we've not seen some of it yet.